Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601112 | 0.76 | NOS1 (0.61) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL476854 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277055 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL18193497 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL4314318 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL5951586 | 0.74 | AXL (0.63) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277054 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL907863 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL155255 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL29692441 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105924385-A | Diarylthiourea compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| CN-102372675-A | 6-chlorine-4-iodine indazole, preparation method and application thereof | SHENZHEN INOVA MEDICAL TECHNOLOGY DEV CO LTD | 2012-03-14 | — | — | CN | claimed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024086664-A2 | COVALENT INHIBITORS OF WILD-TYPE AND MUTANT PI3K AND METHOD OF USES THEREOF | TOTUS MEDICINES INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-3586835-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ARYL ETHERS | PELOTON THERAPEUTICS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4257196-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | The University of Hong Kong (HK) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023183936-A2 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | TOTUS MEDICINES INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2279188-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| CN-101679310-A | Alkynylpyrimidines as Tie2 kinase inhibitors | BAYER SCHERING PHARMA AG | 2010-03-24 | — | — | CN | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009146406-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | NOS1 2543/4885AXL 651/4885IDO1 2180/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | NOS1 3929/4885AXL 1406/4885IDO1 2760/4885 |
| US-20090099219-A1 | ALKYNYLPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | NOS1 61/4885AXL 57/4885IDO1 841/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | NOS1 3265/4885AXL 1235/4885IDO1 3780/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | NOS1 1992/4885AXL 613/4885IDO1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.